Hong Kong Electronic Equipment and Components Stock News

ZJLD Group (SEHK:6979) has issued unaudited earnings guidance for 2025, flagging revenue of around CN¥3.55b to CN¥3.70b and profit of CN¥0.52b to CN¥0.58b, both sharply lower than 2024. See our latest analysis for ZJLD Group. The earnings guidance lands after a strong run in the shares, with a 90 day share price return of 16% and a 1 year total shareholder return of 35.19%. This suggests momentum has been positive even as expectations for 2025 are reset. At the latest share price of HK$9.28,...

Mobvista Inc. recently issued earnings guidance for 2025, projecting revenue of about US$2.03–2.06 billion and profit attributable to equity shareholders of US$54–64 million, citing stable gross margins and better operating efficiency. The company highlighted rapid growth in the mobile advertising and marketing technology industry around its core Mintegral programmatic platform as a key driver of this improved profitability outlook. We will now examine how this guidance, particularly the...

CStone Pharmaceuticals (SEHK:2616) is back on investors radar after the UK regulator granted a new indication for its cancer drug sugemalimab, extending its use in specific stage III lung cancer patients. See our latest analysis for CStone Pharmaceuticals. The MHRA decision lands at a time when CStone’s 1 month share price return of 30.91% and 90 day share price return of 18.75% suggest building momentum. However, the 1 year total shareholder return of 100.30% contrasts with a 5 year total...

Board reshuffle and what it might mean for investors China CITIC Financial Asset Management (SEHK:2799) has just gone through a significant board reshuffle, with three directors departing and new committee chairs and members appointed following its February 28, 2026 board meeting. See our latest analysis for China CITIC Financial Asset Management. At a share price of HK$0.81, China CITIC Financial Asset Management has had a mixed run, with a 1-day share price return of 1.25% but a 90-day...

Sino Biopharmaceutical (SEHK:1177) has drawn fresh investor attention after signing an exclusive global license agreement with Sanofi for its JAK/ROCK inhibitor rovadicitinib, tied to upfront, milestone and royalty payments. See our latest analysis for Sino Biopharmaceutical. The Sanofi licensing news arrives at a time when Sino Biopharmaceutical’s shares trade at HK$6.13, with a 1 day share price return of 3.72% and a year to date share price return decline of 3.62%. However, a 1 year total...

Shanghai Chicmax Cosmetic Co., Ltd. recently issued unaudited 2025 earnings guidance, expecting revenue of about RMB 9,100.0 million to RMB 9,200.0 million and profit of about RMB 1,140.0 million to RMB 1,160.0 million, both rising by more than one third compared with 2024. Management linked this growth outlook mainly to its multi-brand, multi-category approach, highlighting strong momentum in its KANS anti-aging line and a sharp revenue increase from the infant- and child-focused newpage...

China Mobile (SEHK:941) is back in the spotlight as Junlan Feng prepares for a fireside chat titled “The Agentic Imperative” at Mobile World Congress 2026, highlighting the group’s role in advanced network and computing infrastructure. See our latest analysis for China Mobile. Despite the upcoming Mobile World Congress appearance and China’s push into 5G and computing power infrastructure, momentum has cooled recently, with a 90 day share price return showing an 8.36% decline, even as the 5...

Why Greentown China’s latest sales update matters for investors Greentown China Holdings (SEHK:3900) has drawn fresh attention after releasing unaudited operating data for the first two months of 2026, highlighting contracted sales of about RMB18.3b across self-investment and project management projects. See our latest analysis for Greentown China Holdings. Greentown China’s latest contracted sales update lands after a mixed price pattern, with a 1 day share price return of 1.42% and a 30 day...

China Everbright (SEHK:165) is back in focus after a boardroom reshuffle, with Chairman Yu Fachang stepping down, President Lin Chun moving into the Chairman role, and Pan Jianyun taking over as Acting President. See our latest analysis for China Everbright. The leadership reshuffle comes after a mixed price pattern, with a 3.1% 1 day share price return to HK$8.32 contrasting with a 12.42% year to date share price decline. However, the 1 year total shareholder return of 64.63% points to...

NEV growth offsets weaker legacy sales at Dongfeng Motor Group Dongfeng Motor Group (SEHK:489) has drawn investor attention after reporting a 1.2% year-on-year rise in total sales volume for the first two months of 2026, driven by strong new energy vehicle performance. NEV sales climbed 51.8% in this period, with commercial NEV volumes growing by 138.8%. This helped soften the impact of weaker traditional passenger vehicle sales at Dongfeng Nissan and Dongfeng Honda. See our latest analysis...

Why ENN Energy Holdings Just Drew Investor Attention ENN Energy Holdings (SEHK:2688) has come into focus after a recent move in its share price, with the stock closing at HK$68.30 as investors reassess its role in China’s gas infrastructure market. See our latest analysis for ENN Energy Holdings. The recent 1 day share price return of a 2.15% decline and 7 day share price return of a 0.73% decline sit against a 1 year total shareholder return of 33.69%. However, longer term total shareholder...

Sun Art Retail Group (SEHK:6808) has confirmed details of its interim dividend, setting a HK$0.085 per share payout and updating the currency options and exchange rates available to shareholders. See our latest analysis for Sun Art Retail Group. Sun Art Retail Group’s latest dividend update comes after a mixed share price run, with a 5.10% 1 day share price return but a year to date share price decline of 5.17%, and a 5 year total shareholder return loss of 67.73%. This points to fading long...

Pre earnings surge puts China Energy Engineering in focus China Energy Engineering (SEHK:3996) moved into the spotlight after an 8.73% pre market move on March 7, 2026, accompanied by heavy trading volume as investors positioned ahead of the March 27 earnings release. See our latest analysis for China Energy Engineering. Beyond the latest pre market jump, China Energy Engineering’s 1 month share price return of 21.24% and year to date gain of 26.85% suggest that momentum has been building...

BYD stock in focus after recent performance BYD (SEHK:1211) has returned about 2.3% over the past day, with a small decline over the past week and mixed moves over the past month and past 3 months. This has kept investors focused on fundamentals. See our latest analysis for BYD. At around HK$94.7, BYD’s recent 1 day share price return of 2.27% contrasts with a year to date share price return decline of 4.10% and a 1 year total shareholder return decline of 19.13%. This suggests momentum has...

Dividend proposal and earnings results set the tone for Xinyi Glass Xinyi Glass Holdings (SEHK:868) has drawn investor attention after reporting full year 2025 earnings, together with a proposed final cash dividend of HK$0.215 per share that will go to a shareholder vote in May. See our latest analysis for Xinyi Glass Holdings. The latest earnings release and dividend proposal have come alongside a strong run in the share price, with a 90 day share price return of 20.89% and year to date...

Akeso (SEHK:9926) is back in focus after presenting long term survival data for its bispecific antibody cadonilimab in advanced cervical cancer and announcing a new glioblastoma combo trial collaboration with INOVIO. See our latest analysis for Akeso. Akeso shares closed at HK$107.3 after a 5.2% 1 day share price return. While the 30 day share price return of 6.34% contrasts with a 13.75% decline over 90 days, the 47.19% 1 year total shareholder return and 173.03% 3 year total shareholder...

Earnings and dividend decisions put Hong Kong Exchanges and Clearing (SEHK:388) in focus Hong Kong Exchanges and Clearing (SEHK:388) is on investors’ radar after reporting full year 2025 results with revenue of HK$29,161 million and net income of HK$17,754 million, alongside a higher second interim dividend of HK$6.52 per share. See our latest analysis for Hong Kong Exchanges and Clearing. The latest earnings, higher second interim dividend and upcoming board refresh arrive as the shares...

Upcoming board meeting puts focus on results and dividend policy China Oilfield Services (SEHK:2883) has scheduled a board meeting on 24 March 2026 to approve its 2025 annual results and consider a final dividend, giving investors a clear date for key information on earnings and capital returns. See our latest analysis for China Oilfield Services. At a share price of HK$10.2, China Oilfield Services has seen momentum build recently, with a 30 day share price return of 13.97% and a 1 year...

Sales slump and land buys put China Overseas Land & Investment in focus China Overseas Land & Investment (SEHK:688) has come under closer investor scrutiny after reporting a 35.9% year-on-year drop in February 2026 contracted sales value and a 45% decline in sales area. Across January and February 2026, contracted sales value was RMB 22.942b, down 9% year-on-year. At the same time, the group purchased new land in Hong Kong and Baoding that could shape its future project pipeline. See our...

China Mengniu Dairy (SEHK:2319) is back in focus after the company flagged a 7% to 8% revenue decline and slightly lower margins for 2025, alongside plans for sizeable asset impairment provisions. See our latest analysis for China Mengniu Dairy. The revenue warning and impairment plans arrive after a mixed price pattern, with a 1 day share price return of 6.95% at HK$16.16, a 30 day share price return of 8.55%, and a 1 year total shareholder return of 11.88% that extends to 57.69% over five...

InnoCare Pharma (SEHK:9969) has drawn fresh attention after China’s drug regulator granted priority review to its next generation TRK inhibitor zurletrectinib for pediatric NTRK fusion solid tumors, alongside inclusion in the CDE’s SPARK Program. See our latest analysis for InnoCare Pharma. The priority review news comes after a mixed stretch for the shares. A 1-day share price return of 5.44% lifted the stock to HK$11.83, while the 30-day and 90-day share price returns of 7.87% and 17.10%...

CGN New Energy Holdings (SEHK:1811) has announced a leadership change, with long serving chairman and executive director Zhang Zhiwu stepping down due to job arrangements. Hu Guangyao will take over key board roles. See our latest analysis for CGN New Energy Holdings. The leadership reshuffle comes as CGN New Energy Holdings trades at HK$2.78, with recent momentum reflected in a 30 day share price return of 8.59% and a 1 year total shareholder return of 24.26%. This indicates improving...

Why Abbisko Cayman's Latest Earnings Matter for Investors Abbisko Cayman (SEHK:2256) is back in focus after releasing full year 2025 results, reporting sales of CNY612.12 million and net income of CNY55.25 million, alongside basic and diluted EPS of CNY0.09 from continuing operations. See our latest analysis for Abbisko Cayman. The earnings release appears to have shifted sentiment in the short term, with a 1 day share price return of 4.76% to HK$11.88. However, the 90 day share price return...

Why Black Sesame International Holding is back on investor radars Black Sesame International Holding (SEHK:2533) has drawn fresh attention after saying it expects more than 68% year on year revenue growth in 2025 from advanced driver assistance and robotics, while still forecasting a net loss. See our latest analysis for Black Sesame International Holding. The recent profit warning, paired with expectations for over 68% revenue growth and fresh capital from a HK$538 million share...